1 / 21

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation in Taiwan 2009-2012

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation in Taiwan 2009-2012. Taiwan Society of Blood and Marrow Transplantation. National Taiwan University Hospital. Koo Foundation Cancer Center. Veterian General Hospial-Taipei. Tri-Service General Hospital.

neo
Download Presentation

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation in Taiwan 2009-2012

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation in Taiwan2009-2012 Taiwan Society of Blood and Marrow Transplantation

  2. National Taiwan University Hospital Koo Foundation Cancer Center Veterian General Hospial-Taipei Tri-Service General Hospital Far-Eastern Memorial Hospital ChangGung Memeorial Hospital-LinKou Shuang-Ho Hospital Veterian General Hospial-TaiChung Buddist Tzu-Chi Hospital Chinese Medical University Hospital ChangHua Christrian Hospital 14 HSCT centers Chia-Yi Christrian Hospital National ChengKung University Hospital Kaohsiung Medical University Hospital Veterian General Hospial-Kaohsiung ChangGung Memeorial Hospital-Kaohsiung

  3. Cumulative numbers of HSCT, 2009-2012 Allo-BMT 40 -PBSCT 897 -BM+PB 1 -BM+UCB 1 Auto-PBSCT 588 -BMT 1 -BM+PB 2 CBT 11 Total 1541 N 364 415 389 373

  4. Annual Numbers of HSCT, 2009-2012 N=1541

  5. Trends in Transplantation by Recipient Age, 2009-2012 % Autologous Allogeneic

  6. Trends in Transplantation by Recipient Age, 2009-2012 N=594 N=947 % Autologous Allogeneic

  7. Types of Donor, 2009-2012 N=1541

  8. Indications of HSCT by Donor type, 2009-2012 N=1541

  9. Allogeneic transplantations by conditioning regimen intensity and age, 2009-2012

  10. Reasons to do HSCT twice or more, 2009-2012 % N=134 49 remains alive

  11. Numbers of 2nd Malignancy % 15 remains alive

  12. Main cause of death Others: VOD,IP,Hemorrhage,Rejection,New malignancy,Cardiac toxicity

  13. Overall Survival,2009-2012 Disease free survival, 2009-2012 462 dead, 970 alive

  14. Overall survival after HLA-matched sibling donor transplantation for AML, by risk group, 2009-2012

  15. Overall survival after HLA-matched sibling donor transplantation for ALL, by risk group, 2009-2012

  16. Overall survival for Lymphoma, by transplant type, 2009-2012

  17. Overall survival after allogeneic transplantation for MDS/MPD, 2009-2012

  18. Overall survival after allogeneic transplantation for Anemia, by age group, 2009-2012

  19. Overall survival after autologous transplantation for Multiple Myeloma, 2009-2012

  20. Cumulative incidence of relapse, 2009-2012

  21. Treatment related mortality, 2009-2012

More Related